We use cookies to provide you with the best of services and customized features. By continuing to browse this website, you give your informed consent to our Cookie Policy.
Researchers have developed an innovative nano-immune agonist that significantly improves immunotherapy outcomes for melanoma—a highly aggressive and hard-to-treat form of skin cancer.
